

1 **Integration of serum androgens and Sex Hormone-Binding Globulin**
2 **for optimized early detection of aggressive prostate cancer**

3 Olga Lazareva^{1,2,3,4}, Anja Riediger^{1,5,6,7}, Oliver Stegle^{2,3,4}, Holger Sültmann^{6,8},
4 Markus Hohenfellner⁵, Magdalena Görtz^{1,5,6}

5

6 ¹Junior clinical cooperation unit 'Multiparametric Methods for Early Detection of
7 Prostate Cancer', German Cancer Research Center (DKFZ), Heidelberg, Germany

8 ²Division of Computational Genomics and Systems Genetics, German Cancer
9 Research Center (DKFZ), Heidelberg, Germany

10 ³European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg,
11 Germany

12 ⁴Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK

13 ⁵Department of Urology, University Hospital Heidelberg, Heidelberg, Germany

14 ⁶National Center for Tumor Diseases (NCT), Heidelberg, Germany

15 ⁷Faculty of Biosciences, Heidelberg University, Heidelberg, Germany

16 ⁸Division of Cancer Genome Research, German Cancer Consortium (DKTK),
17 German Cancer Research Center (DKFZ), Heidelberg, Germany

18

19

20 Send correspondence to: Magdalena Görtz

21 magdalena.goertz@med.uni-heidelberg.de

22

23

24

25

26

27 **Running title:**

28 Blood markers associated with prostate cancer severity

29

30 **Keywords:**

31 Androstenedione, Dehydroepiandrosterone-Sulfate, Early Detection of Cancer,

32 Prostatic Neoplasms, Prostate-Specific Antigen, Risk Assessment, Sex Hormone-

33 Binding Globulin

34

35

36 **Word count abstract:** 298 / 300

37 **Word count text:** 3000 / 3000

38

39

40 **ABSTRACT**

41

42 **Background**

43 Aggressive prostate cancer (PC) represents a significant health concern worldwide.
44 Conventional initial screening methods, primarily based on prostate-specific antigen
45 (PSA) levels, lack specificity, leading to a high rate of unnecessary biopsies and an
46 urgent need for more accurate diagnostic tools. This study addresses the gap by
47 exploring the potential of integrating clinical and routine blood laboratory parameters
48 including a comprehensive hormone assessment to enhance the non-invasive
49 prediction of aggressive PC.

50 **Methods**

51 In a pilot study of 578 patients who were scheduled for a prostate biopsy due to
52 suspicion of PC, we analyzed an extensive panel of 28 laboratory values alongside
53 data on family history, diet, and lifestyle. A logistic regression classifier was
54 developed, and model performance was evaluated using repeated k-fold cross-
55 validation on the complete dataset (n=282). Participants were histologically
56 categorized into three risk groups: healthy, moderate PC (ISUP 1-2 PC), and
57 aggressive PC (ISUP 3-5 PC).

58 **Results**

59 Significant associations were found between PC aggressiveness and lower levels of
60 androstenedione, Dehydroepiandrosterone-Sulfate (DHEA-S) and free PSA
61 percentage, as well as higher levels of Sex Hormone Binding Globulin (SHBG). The
62 integration of these serum markers with clinical parameters into a new multi-stage
63 risk classifier for PC prediction significantly improved the predictive accuracy. The
64 risk model outperformed PSA-only methods, demonstrating higher sensitivity and
65 specificity in predicting aggressive PC.

66 **Conclusions**

67 Incorporating serum markers DHEA-S, androstenedione, and SHBG into a novel risk
68 classifier can improve early detection of aggressive PC. These widely available and
69 cost-effective blood biomarkers could reduce reliance on invasive prostate biopsies
70 and expensive magnetic resonance imaging by providing a more targeted approach
71 to non-invasive prediction of aggressive PC following PSA testing. Our pilot study
72 lays the groundwork for larger-scale research to further explore the integration of
73 androgens and SHBG in future risk stratification models for improved clinical decision
74 making.

75

76

77

78

79

80

81

82

83

84

85 INTRODUCTION

86 Prostate cancer (PC) is the second most prevalent cancer in men, representing 27%
87 of all new cancer diagnoses in males (1). It is a major cause of mortality worldwide,
88 with projections of the Lancet Commission on PC indicating a doubling of new cases
89 between 2020 and 2040, particularly in low-income countries (2). Early diagnosis
90 through screening can offer numerous benefits such as a higher likelihood of cure,
91 less aggressive treatment options, reduced progression to metastatic stages, and
92 improved quality of life (3–5). Prostate-specific antigen (PSA) screening is a widely
93 used method for early detection of PC. Recent results from the Rotterdam Section of
94 the European Randomized Study of Screening for PC indicate that PSA screening
95 can substantially reduce long-term mortality rates (6). However, PSA testing has
96 limited specificity, frequently resulting in unnecessary biopsies and the detection of
97 indolent PC (7).

98 To address the limitations of PSA testing, the American Urological Association (AUA)
99 guidelines recommend integrating risk calculators into the traditional decision-making
100 process for PC screening (8). The primary tool is the PSA blood test, and for cases
101 with elevated PSA levels, the AUA guidelines advise using risk calculators that
102 include PSA, free PSA %, age, ethnicity, and family history for personalized risk
103 assessment. Clinicians are then encouraged to engage in shared decision-making
104 with patients, discussing the value of additional diagnostic data from biomarkers or
105 multiparametric magnetic resonance imaging (mpMRI) and considering the
106 advisability of proceeding with a biopsy. Similarly, the European Association of
107 Urology (EAU) recommends using risk stratification nomograms for patients with
108 elevated PSA, including age, family history, digital rectal examination (DRE), prostate
109 volume, and PSA density (PSAD) (9). This method helps to identify men at low risk

110 who may only require clinical follow-up, thereby reducing the need for expensive or
111 invasive tests such as mpMRI and biopsy.

112 mpMRI and fusion-targeted biopsy of suspicious mpMRI lesions are advanced
113 diagnostic methods for PC, significantly enhancing detection accuracy (10,11). High
114 cost and restricted availability of mpMRI, especially in low-resource settings, limit its
115 routine use as a screening tool (12). The economic and logistical challenges of MRI
116 highlight the need for cost-effective and accessible biomarkers to facilitate broader
117 implementation across diverse healthcare settings, improving early detection
118 capabilities.

119 Recent research increasingly focuses on modifiable risk factors, such as lifestyle and
120 diet, associated with PC risk (13,14). Metabolic changes linked to many diseases,
121 including cancer, are reflected in human blood metabolomic patterns, which provide
122 valuable insights into underlying physiological states (15). Systemic information from
123 blood parameters, such as C-reactive protein, amino acids, and glycated hemoglobin,
124 has been predictive of multiple cancers (16). Additionally, adrenal androgens
125 influence the aetiopathogenesis of PC and are associated with aggressive PC
126 (17),(18).

127 The study aimed to improve non-invasive prediction of aggressive PC by integrating
128 44 laboratory and clinical parameters into a predictive model. Our findings
129 demonstrate that incorporating these parameters after PSA testing significantly
130 improved diagnostic accuracy. This approach could reduce unnecessary biopsies,
131 decrease the number of costly MRIs, and more accurately predict PC
132 aggressiveness, aligning with precision medicine principles. By validating a
133 multifaceted diagnostic strategy over traditional PSA-only methods, our research
134 supports a more nuanced approach to PC screening and decision-making.

135 **MATERIALS AND METHODS**

136 **Study population**

137 565 men who received a prostate biopsy at the University Hospital Heidelberg
138 between June 2021 and December 2023 were recruited for supplementary clinical
139 and, if a preoperative blood sample had to be taken and patient consent was given,
140 laboratory values assessment. They were eligible for study inclusion in case of
141 suspicion of PC with a PSA level ≥ 3 ng/ml and/or suspicious DRE and no previous
142 treatment for PC. Additionally, 13 healthy men with a PSA < 2.5 ng/ml who presented
143 to the Urology Clinic at Heidelberg University Hospital for benign conditions, were
144 recruited to enlarge the healthy control group. Data was collected prospectively, and
145 institutional review board approval was obtained (S-130/2021). Clinical information
146 regarding family history (defined as having a first-degree relative with PC), lifestyle,
147 etc. was assessed via questionnaire. Laboratory parameters included, among others,
148 lipid metabolism, inflammatory markers, hormones, and vitamins (**Supplementary**
149 **Table 1**). After obtaining informed consent, blood samples were collected via vein
150 puncture between 8 and 11 AM in fasting patients. All blood samples were analyzed
151 in the central laboratory of Heidelberg University Hospital, in addition to the standard
152 preoperative lab values. The central laboratory of Heidelberg University Hospital has
153 been accredited according to DIN EN ISO 15189 since 2005.

154 **Prostate biopsy**

155 Prebiopsy mpMRI was performed on 543 patients with suspicion of PC and eligibility
156 for mpMRI. All mpMRI scans followed the PI-RADS recommendations, according to
157 European Society of Urogenital Radiology guidelines (19). Men underwent

158 transperineal fusion-targeted biopsy using a UroNav system (Philips Invivo,
159 Gainesville, FL, USA) of MRI-suspicious lesions and saturation biopsy adjusted to
160 prostate volume, as previously described (20,21). Histopathological analyses were
161 performed according to International Society of Urological Pathology (ISUP)
162 standards. The participants were categorized into three risk groups: healthy patients
163 (PSA <2.5 ng/ml or no PC in biopsy), moderate PC (ISUP 1-2 PC), and aggressive
164 PC (ISUP 3-5 PC)(10).

165 **Statistical analysis**

166 In this study, 28 laboratory and 16 clinical parameters were analyzed to determine
167 their impact on PC risk. Each parameter was initially tested for its ability to
168 discriminate between the three predefined risk groups: healthy patients (n=253),
169 moderate PC (n=229), and aggressive PC (n=96) through statistical analysis. For
170 continuous variables, an ordinary least squares (OLS) methodology was employed,
171 fitting models for each parameter to predict the risk groups and subsequently testing
172 the significance of the slope coefficients β_1^k :

$$173 \quad y = \beta_0^k + \beta_1^k x^k,$$

174 where $y \in \{0,1,2\}$ is a risk category corresponding to healthy patients, ISUP 1-2 and
175 ISUP 3-5 PC, β_0^k and β_1^k are intercept and slope coefficients for the k -th tested
176 parameter x^k .

177 For categorical variables the Chi-square test was used (22). All p-values were
178 reported and subsequently adjusted for multiple comparisons using the Benjamini &
179 Hochberg correction (23) with a family-wise error rate at 0.1 level. Complete results
180 are provided in **Supplementary Table 1**, with significant findings highlighted in
181 **Figure 1**.

182 Risk Modeling

183 Risk modeling was performed on 282 patients who had available data for clinical and
184 laboratory parameters, showing a significant association with ISUP grade. The
185 logistic regression model was developed in a staged approach:

- 186 • 1. Baseline model: Initiated with PSA, the standard marker for PC screening,
187 to establish a benchmark for model performance.
- 188 • 2. Serum marker integration: Added laboratory measurements that showed a
189 statistically significant association with PC risk, including Androstenedione,
190 free PSA %, Dehydroepiandrosterone-sulfate (DHEA-Sulfate), and Sex
191 Hormone Binding Globulin (SHBG) to evaluate improvements in sensitivity and
192 specificity.
- 193 • 3. Clinical parameter integration: Included clinical factors from international
194 guidelines (age, family history, DRE results, prostate volume, and PSAD) to
195 assess their combined predictive value.
- 196 • 4. MRI results: Added PIRADS scores to capture additional risk information
197 provided by imaging.
- 198 • 5. Advanced baseline model: Combined MRI and PSA.

199 Model performance was assessed at each stage by calculating the F1 score,
200 Precision, Recall, and Accuracy. The model was evaluated using a repeated k-fold
201 cross-validation ($k = 10$, repeated 10 times) approach, and all performance metrics
202 were reported based on the test set ($n=282$). We used 'L2' regularization to decrease
203 overfitting probability with the default regularization strength ($\lambda = 1$) using scikit-learn
204 models (24).

205 **Interpretative Analysis Using SHAP Values**

206 To understand the influence of individual variables on predictive outcomes, SHAP
207 (SHapley Additive exPlanations) methodology was applied, following the approach
208 proposed by Lundberg and Lee (25). This method quantitatively measured the impact
209 of each parameter included in the model, providing clear insights into how specific
210 factors contribute to overall risk prediction.

211 **RESULTS**

212 **Patient cohort description**

213 The study included a total of 578 patients. During the initial phase of the analysis,
214 when statistically significant markers were selected, all available measurements were
215 used without restricting to a fully overlapping cohort, maximizing the use of the data.
216 Each laboratory parameter was represented by a minimum of 314 and a maximum of
217 353 measurements, while other parameters ranged from 314 to 578 measurements.
218 A comprehensive list of these parameters and their respective counts is provided in
219 **Supplementary Table 1**.

220 Following feature selection, the cohort was refined to include only patients with
221 complete data across all parameters identified as significant (post-multiple hypothesis
222 correction). This subset comprised 282 patients. Detailed descriptions of these
223 patients and their corresponding data are presented in **Table 1**.

224 **Role of blood biomarkers in prostate cancer**

225 Significant associations were found between hormonal markers and PC severity as
226 classified by ISUP grades (**Figure 1**). Lower levels of androstenedione and DHEA-
227 Sulfate were significantly associated with more aggressive forms of PC (ISUP grades

228 3-5) (corrected p-values 0.013 and 0.03, respectively). This finding supports the
229 hypothesis that reductions in certain androgens may signal advanced disease.

230 The bioavailability of circulating androgens is largely determined by the concentration
231 of SHBG. Accordingly, in our study higher levels of SHBG were associated with
232 increased PC severity (corrected p-value 0.037).

233 Higher PSA levels were positively correlated with PC severity (corrected p-value
234 0.03). Additionally, a lower percentage of free PSA % indicated more aggressive
235 cancer (corrected p-value 0.025). These results reinforce the role of PSA and free
236 PSA percentage as critical biomarkers in assessing PC aggressiveness.

237 **Incorporating clinical and lab values into new risk models for non-invasive** 238 **prostate cancer prediction**

239 In developing a PC risk classifier, we included the five significant laboratory values,
240 along with clinical features and imaging parameters, that were strongly associated
241 with ISUP grades. Age, DRE results, PSAD, PIRADS scores, and prostate volume
242 showed statistically significant associations with ISUP grade severity, all with
243 corrected p-values <0.05. Although a family history of PC did not show a significant
244 statistical association with ISUP grades (corrected p-value 0.552), it was included in
245 the model to adhere to AUA and EAU guidelines (8,9).

246 The performance of the risk classifier was evaluated through a multi-stage approach:
247 1. Baseline model initiated with PSA, 2. Enhancement with laboratory biomarkers
248 significantly associated with PC risk (Androstenedione, free PSA %, DHEA-Sulfate,
249 and SHBG), 3. Integration of clinical factors (Age, family history, DRE results,
250 prostate volume, and PSAD), 4. Integration of MRI results (PIRADS scores) and 5.
251 Advanced baseline model with solely PSA and MRI as comparison. This stepwise
252 model enhancement resulted in gradual improvements across all metrics from stage

253 1-4, including F1 score, precision, recall, and accuracy. The progression of median
254 scores through each stage is depicted in **Figure 2A**, with exact values provided in
255 **Supplementary Table 2**.

256 The regression coefficient distribution was analyzed to assess the prognostic
257 significance of each parameter (**Figure 2B**). PSAD emerged as a particularly
258 influential factor in identifying healthy patients. Established diagnostic parameters like
259 PSA, DRE results and PIRADS also showed high importance for non-invasive
260 prediction of PC presence. However, with these parameters, coefficients for ISUP
261 grades 1-2 and 3-5 PC often shared the same sign, indicating challenges in
262 differentiating these two categories. Serum androgens displayed variable signs for
263 ISUP 1-2 versus ISUP 3-5 PC, suggesting their potential impact on the model's
264 predictive capability.

265 **Influence of individual variables on predictive outcomes using SHAP Values**

266 To understand the influence of individual variables on predictive outcomes for each
267 patient, we employed SHAP analysis to obtain per-patient SHAP values. These
268 values help to identify the specific factors contributing to each patient's prediction (PC
269 versus no PC) and provide insight into the influence of each variable on the
270 predictive outcomes. The model was developed to assist urologists in making
271 informed decisions regarding prostate biopsies, especially when the complexity of
272 individual patient profiles challenges clinical judgement. Values from two study
273 patients are shown where biopsies didn't reveal PC, and the model correctly
274 predicted the absence of PC, demonstrating the practical utility of SHAP analysis as
275 a transparent, data-driven foundation for clinicians (**Figure 3A and 3B**).

276 **DISCUSSION**

277 This study aimed to improve the non-invasive prediction of aggressive PC by
278 integrating clinical and laboratory parameters into a comprehensive risk model. By
279 identifying novel, cost-effective serum markers, we sought to improve decision-
280 making following PSA testing and reduce reliance on invasive procedures and
281 expensive MRI use.

282 Our study revealed several results. First, levels of DHEA sulfate and
283 androstenedione were significantly reduced in newly diagnosed aggressive PC
284 compared to healthy controls. In line with these results, higher levels of SHBG were
285 significantly associated with increased PC aggressiveness. These markers had a
286 stronger association with aggressive PC detection than established variables advised
287 for use in risk stratification nomograms, such as family history (8,9). Thus, androgens
288 have potential as diagnostic markers for early detection of aggressive PC, offering a
289 complementary diagnostic tool alongside PSA testing. Androgens were particularly
290 effective in distinguishing between ISUP 1-2 and ISUP 3-5 PC, highlighting their
291 potential in differentiating moderate from aggressive PC, e.g. for treatment
292 approaches such as active surveillance (26). ISUP 1-2 PC patients may be offered
293 active surveillance instead of radical therapy due to the indolent nature of their
294 disease (27). Existing biomarkers expressed by all PC, including indolent tumors,
295 offer limited potential to selectively detect high-grade disease (28). Novel biomarkers
296 distinguishing high-grade from low-grade PC are urgently needed, aligning with
297 guidelines emphasizing a focus on high-grade PC due to the indolent nature of low-
298 grade PC (8).

299 Second, integrating clinical findings and laboratory values into the decision-making
300 process for recommending MRI scans has the potential to improve the selection of
301 patients who benefit most from imaging. MRI remains time- and resource-intensive

302 and may pose considerable costs for patients, apart from limitations in availability and
303 inter-rater reliability. Barriers in healthcare delivery limit the wide adoption of MRI in
304 real-world practice as a diagnostic test following PSA. The decision to use MRI and
305 fusion biopsy can be supported by relatively inexpensive routine blood values and
306 clinical parameters, minimizing unnecessary MRIs for PSA-positive patients with a
307 low likelihood of PC. Commercially available blood values are straightforward to
308 implement and less resource-intensive, allowing urologists to more selectively apply
309 MRI and/or biopsy (29,30). Our results support implementing integrated decision-
310 making frameworks in clinical routine to optimize MRI and biopsy use in PC
311 diagnostics.

312 Third, the application of an explainable decision support concept in our study
313 demonstrates an approach to guide urologists and patients in making informed
314 decisions regarding prostate biopsies. A transparent and comprehensive assessment
315 of each patient's clinical scenario, including evaluation of clinical, lab values, and, if
316 applicable, MRI findings, allows urologists and patients to make trustworthy and
317 clinically justified decisions.

318 Our findings align with previous research, such as Severi et al., who found high levels
319 of adrenal androgens like androstenedione and DHEA Sulfate associated with a
320 reduced risk of aggressive PC (31). Their study of 17,049 men reported that double
321 concentrations of androstenedione were associated with almost half the risk of
322 aggressive PC, and double concentrations of DHEA-Sulfate were associated with a
323 37% lower risk. Additionally, Travis et al. described an inverse association of the
324 androstenedione concentration with advanced PC (32).

325 Our finding of higher SHBG levels in ISUP 3-5 PC complements previous results that
326 proposed SHBG as a marker of aggressive PC in early-stage disease. Preoperative
327 serum SHBG levels were an independent predictor of extraprostatic extension in

328 localized PC, suggesting a role of SHBG in PC progression (33). A study by Price et
329 al. demonstrated that germline genetic variations of androgen-related pathway genes
330 are associated with serum androgen and SHBG concentrations and PC risk (34).

331 Routine blood test results harbor valuable information that may not be immediately
332 apparent to clinicians. Podnar et al. demonstrated the feasibility of brain tumor
333 diagnosis from routine blood tests using a machine learning predictive model with
334 diagnostic accuracy comparable to imaging studies (35). Regular screening with
335 blood tests for disease prevention is already recommended in many countries (36).
336 This study's results indicate the potential of simple clinical parameters combined with
337 comprehensive laboratory predictors to estimate aggressive PC risk. Highlighting
338 androgens as complementary diagnostic tools at minimal cost and emphasizing an
339 integrated approach to MRI utilization could lead to more efficient screening
340 strategies for aggressive PC.

341 Several promising additional biomarkers could complement the current diagnostic
342 pathway for PC, including PSA derivatives and genetic markers (37). Combining the
343 prostate health index and the 4K score (38), if available, with widely accessible and
344 cost-effective clinical and lab values may offer a comprehensive and accurate
345 approach for early non-invasive prediction of aggressive PC. Recognizing the low
346 specificity of PSA as a challenge for PC screening programs, Srivastava et al.
347 recently proposed a "more is more" approach in PC screening programs with the
348 addition of biomarkers in a multistep approach (30). This strategy could help to
349 optimize biopsy decisions, reduce unnecessary biopsies, and improve patient
350 outcomes.

351 Several limitations must be acknowledged. The pilot study's sample size may limit
352 the generalizability and statistical power of the findings. Validation in independent,
353 larger cohorts is necessary to ensure the classifier's robustness and generalizability.

354 The study population was from a single center, lacking diversity in ethnicity and
355 geographic factors, which may affect the applicability of results to all populations.
356 Identified serum markers, DHEA, SHBG, and androstenedione, need further
357 investigation to validate their efficacy and reliability across diverse populations and
358 their potential for prevention, detection and prognosis of early-stage, aggressive PC.
359 Additionally, the study's nature did not allow determining causal relationships among
360 variables. Longitudinal studies are necessary to establish relationships between
361 hormone levels and PC development or progression. Lastly, the definition of PC that
362 is aggressive and requires active treatment rather than active surveillance is
363 controversial, with varying definitions of aggressive PC. As ISUP 1-2 PC patients can
364 be offered active surveillance due to the indolent nature of the disease, histological
365 assessment was used to stratify patients into moderate (ISUP 1-2) and aggressive
366 (ISUP 3-5) PC (10,21).

367 **CONCLUSIONS**

368 Incorporating serum markers DHEA-S, androstenedione, and SHBG into a novel risk
369 classifier can improve early detection of aggressive PC. These widely available and
370 cost-effective blood biomarkers could reduce reliance on invasive prostate biopsies
371 and expensive MRI by providing a more targeted approach to non-invasive prediction
372 of aggressive PC following PSA testing. Our pilot study lays the groundwork for
373 larger-scale research to further explore the integration of androgens and SHBG in
374 future risk stratification models for improved clinical decision making.

375

376

377

378

379

380 **ABBREVIATIONS**

381	AUA	American Urological Association
382	DHEA	Dehydroepiandrosterone
383	DRE	Digital rectal examination
384	EAU	European Association of Urology
385	ISUP	International Society of Urological Pathology
386	mpMRI	Multiparametric magnetic resonance
387		imaging
388	PC	Prostate cancer
389	PSA	Prostate-specific antigen
390	PSAD	Prostate-specific antigen density
391	SHBG	Sex Hormone Binding Globulin

392

393 **DECLARATIONS**

394 **Conflicting interests:** None.

395 **Funding:** This work was realized through support by the German Federal Ministry for
396 Economic Affairs and Climate Action (funding # 01MT21004A) and the Dieter
397 Morszeck Foundation.

398 **Ethical approval:** The study was approved by the ethical committee of the University
399 of Heidelberg (Approval No. S-130/2021) and was performed in accordance with the
400 Declaration of Helsinki.

401 **Contributorship:** Conceptualization: M.G.; Data curation: A.R., O.L.; Formal
402 analysis: O.L.; Funding acquisition: M.G., M.H.; Investigation: H.S.; M.G., O.L;
403 Methodology: H.S.; M.G., O.L.; Project Administration: M.G.; Resources: M.G., M.H.,
404 O.S.; Software: O.L., O.S.; Supervision: M.G.; Validation: A.R., H.S., O.L.;

405 Visualization: O.L.; Writing - original draft: M.G., O.L.; Writing - review & editing: A.R.,
406 H.S., M.H., O.S.

407 All authors critically reviewed, edited, and added to the manuscript as well as
408 approved the final version of the manuscript.

409 **Acknowledgements:**

410 We sincerely thank Daniela Janscho for her invaluable assistance in handling patient
411 samples.

412 **Data availability statement:**

413 The data sets generated during and analyzed during the current study are available
414 from the corresponding author on reasonable request.

415 **Declaration of generative AI and AI-assisted technologies in the writing
416 process:**

417 During the preparation of this work the authors used ChatGPT-4o in order to improve
418 language and readability. After using this tool, the authors reviewed and edited the
419 content as needed and take full responsibility for the content of the publication.

420

421

422

423 **REFERENCES**

- 424 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer*
425 *J Clin.* 2022 Jan;72(1):7–33.
- 426 2. James ND, Tannock I, N'Dow J, Feng F, Gillessen S, Ali SA, et al. The Lancet
427 Commission on prostate cancer: planning for the surge in cases. *The Lancet*
428 [Internet]. 2024 Apr 27 [cited 2024 Jul 23];403(10437):1683–722. Available from:
429 [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(24\)00651-2/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00651-2/fulltext)
- 430 3. Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Zappa M, Nelen V, et
431 al. Screening and prostate cancer mortality: results of the European Randomised
432 Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. *Lancet*
433 *Lond Engl.* 2014 Dec 6;384(9959):2027–35.
- 434 4. Schröder FH, Hugosson J, Carlsson S, Tammela T, Määttänen L, Auvinen A,
435 et al. Screening for prostate cancer decreases the risk of developing metastatic
436 disease: findings from the European Randomized Study of Screening for Prostate
437 Cancer (ERSPC). *Eur Urol.* 2012 Nov;62(5):745–52.
- 438 5. Van Poppel H, Albrecht T, Basu P, Hogenhout R, Collen S, Roobol M. Serum
439 PSA-based early detection of prostate cancer in Europe and globally: past, present
440 and future. *Nat Rev Urol.* 2022 Sep;19(9):562–72.
- 441 6. de Vos II, Meertens A, Hogenhout R, Remmers S, Roobol MJ, ERSPC
442 Rotterdam Study Group. A Detailed Evaluation of the Effect of Prostate-specific
443 Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year
444 Follow-up Results of the Rotterdam Section of the European Randomised Study of
445 Screening for Prostate Cancer. *Eur Urol.* 2023 Oct;84(4):426–34.
- 446 7. Roobol MJ, Steyerberg EW, Kranse R, Wolters T, van den Bergh RCN,
447 Bangma CH, et al. A risk-based strategy improves prostate-specific antigen-driven

- 448 detection of prostate cancer. *Eur Urol*. 2010 Jan;57(1):79–85.
- 449 8. Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, et al. Early
450 Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a
451 Prostate Biopsy. *J Urol [Internet]*. 2023 Jul [cited 2024 May 29];210(1):54–63.
452 Available from: <https://www.auajournals.org/doi/10.1097/JU.0000000000003492>
- 453 9. Van Poppel H, Roobol MJ, Chapple CR, Catto JWF, N'Dow J, Sønksen J, et
454 al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection
455 Strategy for Prostate Cancer: European Association of Urology Position and
456 Recommendations for 2021. *Eur Urol [Internet]*. 2021 Dec 1 [cited 2024 Aug
457 15];80(6):703–11. Available from:
458 <https://www.sciencedirect.com/science/article/pii/S0302283821019278>
- 459 10. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et
460 al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer
461 (PROMIS): a paired validating confirmatory study. *Lancet Lond Engl*. 2017 Feb
462 25;389(10071):815–22.
- 463 11. Rouvière O, Puech P, Renard-Penna R, Claudon M, Roy C, Mège-
464 Lechevallier F, et al. Use of prostate systematic and targeted biopsy on the basis of
465 multiparametric MRI in biopsy-naïve patients (MRI-FIRST): a prospective,
466 multicentre, paired diagnostic study. *Lancet Oncol*. 2019 Jan;20(1):100–9.
- 467 12. van der Leest M, Israël B, Cornel EB, Zámečník P, Schoots IG, van der Lelij H,
468 et al. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols
469 for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic
470 Resonance Imaging Accessibility. *Eur Urol [Internet]*. 2019 Nov 1 [cited 2024 May
471 29];76(5):574–81. Available from:
472 <https://www.sciencedirect.com/science/article/pii/S0302283819304361>
- 473 13. Peisch SF, Van Blarigan EL, Chan JM, Stampfer MJ, Kenfield SA. Prostate

- 474 cancer progression and mortality: a review of diet and lifestyle factors. *World J Urol.*
475 2017 Jun;35(6):867–74.
- 476 14. Plym A, Zhang Y, Stopsack KH, Delcoigne B, Wiklund F, Haiman C, et al. A
477 Healthy Lifestyle in Men at Increased Genetic Risk for Prostate Cancer. *Eur Urol.*
478 2023 Apr;83(4):343–51.
- 479 15. Deelen J, Kettunen J, Fischer K, van der Spek A, Trompet S, Kastenmüller G,
480 et al. A metabolic profile of all-cause mortality risk identified in an observational study
481 of 44,168 individuals. *Nat Commun [Internet].* 2019 Aug 20 [cited 2024 May
482 29];10(1):3346. Available from: <https://www.nature.com/articles/s41467-019-11311-9>
- 483 16. Kok DEG, van Roermund JGH, Aben KKH, den Heijer M, Swinkels DW,
484 Kampman E, et al. Blood lipid levels and prostate cancer risk; a cohort study.
485 *Prostate Cancer Prostatic Dis.* 2011 Dec;14(4):340–5.
- 486 17. Watts EL, Perez-Cornago A, Fensom GK, Smith-Byrne K, Noor U, Andrews
487 CD, et al. Circulating free testosterone and risk of aggressive prostate cancer:
488 Prospective and Mendelian randomisation analyses in international consortia. *Int J*
489 *Cancer [Internet].* 2022 Oct 1 [cited 2024 May 29];151(7):1033–46. Available from:
490 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613289/>
- 491 18. Dobbs RW, Malhotra NR, Greenwald DT, Wang AY, Prins GS, Abern MR.
492 Estrogens and prostate cancer. *Prostate Cancer Prostatic Dis.* 2019 May;22(2):185–
493 94.
- 494 19. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2 -
495 PubMed [Internet]. [cited 2024 May 29]. Available from:
496 <https://pubmed.ncbi.nlm.nih.gov/26427566/>
- 497 20. Görtz M, Radtke JP, Hatiboglu G, Schütz V, Tosev G, Güttlein M, et al. The
498 Value of Prostate-specific Antigen Density for Prostate Imaging-Reporting and Data
499 System 3 Lesions on Multiparametric Magnetic Resonance Imaging: A Strategy to

- 500 Avoid Unnecessary Prostate Biopsies. *Eur Urol Focus* [Internet]. 2021 Mar 1 [cited
501 2024 May 29];7(2):325–31. Available from: [https://www.eu-](https://www.eurofocus.europeanurology.com/article/S2405-4569(19)30353-0/fulltext)
502 [focus.europeanurology.com/article/S2405-4569\(19\)30353-0/fulltext](https://www.eurofocus.europeanurology.com/article/S2405-4569(19)30353-0/fulltext)
- 503 21. Radtke JP, Schwab C, Wolf MB, Freitag MT, Alt CD, Kesch C, et al.
504 Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound
505 Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy
506 Specimen. *Eur Urol*. 2016 Nov;70(5):846–53.
- 507 22. Pearson K. X. On the criterion that a given system of deviations from the
508 probable in the case of a correlated system of variables is such that it can be
509 reasonably supposed to have arisen from random sampling. *Lond Edinb Dublin*
510 *Philos Mag J Sci* [Internet]. 1900 Jul 1 [cited 2024 Jun 5];50(302):157–75. Available
511 from: <https://doi.org/10.1080/14786440009463897>
- 512 23. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical
513 and Powerful Approach to Multiple Testing. *J R Stat Soc Ser B Methodol* [Internet].
514 1995 [cited 2024 Jun 7];57(1):289–300. Available from:
515 <https://onlinelibrary.wiley.com/doi/abs/10.1111/j.2517-6161.1995.tb02031.x>
- 516 24. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al.
517 Scikit-learn: Machine Learning in Python. *J Mach Learn Res* [Internet]. 2011 [cited
518 2024 Sep 2];12(85):2825–30. Available from:
519 <http://jmlr.org/papers/v12/pedregosa11a.html>
- 520 25. Lundberg SM, Lee SI. A Unified Approach to Interpreting Model Predictions.
521 In: *Advances in Neural Information Processing Systems* [Internet]. Curran
522 Associates, Inc.; 2017 [cited 2024 May 31]. Available from:
523 [https://papers.nips.cc/paper_files/paper/2017/hash/8a20a8621978632d76c43dfd28b](https://papers.nips.cc/paper_files/paper/2017/hash/8a20a8621978632d76c43dfd28b67767-Abstract.html)
524 [67767-Abstract.html](https://papers.nips.cc/paper_files/paper/2017/hash/8a20a8621978632d76c43dfd28b67767-Abstract.html)
- 525 26. Ploussard G, Isbarn H, Briganti A, Sooriakumaran P, Surcel CI, Salomon L, et

- 526 al. Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate
527 cancer? A multi-institutional study of 2,323 patients. *Urol Oncol*. 2015
528 Feb;33(2):71.e1-9.
- 529 27. Albuquerque-Castro Â, Macedo-Silva C, Oliveira-Sousa R, Constâncio V,
530 Lobo J, Carneiro I, et al. Redefining prostate cancer risk stratification: a pioneering
531 strategy to estimate outcome based on Ki67 immunoscore. *Biomark Res [Internet]*.
532 2024 [cited 2024 Aug 15];12(1). Available from:
533 <https://link.springer.com/epdf/10.1186/s40364-024-00627-4>
- 534 28. Tosoian JJ, Zhang Y, Xiao L, Xie C, Samora NL, Niknafs YS, et al.
535 Development and Validation of an 18-Gene Urine Test for High-Grade Prostate
536 Cancer. *JAMA Oncol*. 2024 Jun 1;10(6):726–36.
- 537 29. Jiao B, Gulati R, Hendrix N, Gore JL, Rais-Bahrami S, Morgan TM, et al.
538 Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests
539 in Men With Intermediate Prostate-Specific Antigen Levels in the United States.
540 *Value Health [Internet]*. 2021 Aug 1 [cited 2024 Jul 23];24(8):1111–7. Available from:
541 <https://www.sciencedirect.com/science/article/pii/S1098301521001649>
- 542 30. Srivastava A, Lewicki P, Morgan TM. Biomarkers in Prostate Cancer
543 Screening: Sometimes “More is More.” *Eur Urol [Internet]*. 2024 Jun 18 [cited 2024
544 Jul 23]; Available from:
545 <https://www.sciencedirect.com/science/article/pii/S030228382402428X>
- 546 31. Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, et al.
547 Circulating steroid hormones and the risk of prostate cancer. *Cancer Epidemiol
548 Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol*. 2006
549 Jan;15(1):86–91.
- 550 32. Travis RC, Key TJ, Allen NE, Appleby PN, Roddam AW, Rinaldi S, et al.
551 Serum androgens and prostate cancer among 643 cases and 643 controls in the

- 552 European Prospective Investigation into Cancer and Nutrition. *Int J Cancer* [Internet].
553 2007 [cited 2024 Jul 23];121(6):1331–8. Available from:
554 <https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.22814>
- 555 33. Lee SE, Chung JS, Han BK, Park CS, Moon KH, Byun SS, et al. Preoperative
556 Serum Sex Hormone-Binding Globulin as a Predictive Marker for Extraprostatic
557 Extension of Tumor in Patients with Clinically Localized Prostate Cancer. *Eur Urol*
558 [Internet]. 2008 Dec 1 [cited 2024 Aug 15];54(6):1324–32. Available from:
559 <https://www.sciencedirect.com/science/article/pii/S0302283808002649>
- 560 34. Price DK, Chau CH, Till C, Goodman PJ, Leach RJ, Johnson-Pais TL, et al.
561 Association of Androgen Metabolism Gene Polymorphisms with Prostate Cancer
562 Risk and Androgen Concentrations: Results from the Prostate Cancer Prevention
563 Trial. *Cancer* [Internet]. 2016 Aug 1 [cited 2024 Jul 23];122(15):2332–40. Available
564 from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956504/>
- 565 35. Podnar S, Kukar M, Gunčar G, Notar M, Gošnjak N, Notar M. Diagnosing
566 brain tumours by routine blood tests using machine learning. *Sci Rep* [Internet]. 2019
567 Oct 9 [cited 2024 Jun 7];9(1):14481. Available from:
568 <https://www.nature.com/articles/s41598-019-51147-3>
- 569 36. nhs.uk [Internet]. 2023 [cited 2024 Jun 7]. NHS Health Check. Available from:
570 <https://www.nhs.uk/conditions/nhs-health-check/>
- 571 37. Eickelschulte S, Riediger AL, Angeles AK, Janke F, Duensing S, Sültmann H,
572 et al. Biomarkers for the Detection and Risk Stratification of Aggressive Prostate
573 Cancer. *Cancers* [Internet]. 2022 Dec 11 [cited 2024 Jun 5];14(24):6094. Available
574 from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777028/>
- 575 38. Duffy MJ. Biomarkers for prostate cancer: prostate-specific antigen and
576 beyond. *Clin Chem Lab Med*. 2020 Feb 25;58(3):326–39.1
- 577

578 **Table 1 – Patient characteristics (modeling cohort n = 282) in the healthy, ISUP**
 579 **1-2 PC vs. ISUP 3-5 PC groups for significant parameters. For continuous**
 580 **parameters, median and IQR are provided, otherwise, count per group and**
 581 **percentage are shown.**

582

Parameter	Unit	Healthy patients (n=122)	ISUP 1-2 PC (n=117)	ISUP 3-5 PC (n=43)
Age	Years	63 (57-69)	66 (61-73)	72 (64.50-75)
PSA	ng/dl	5.75 (4.47-8.06)	5.81 (4.2-8.41)	10.11 (6.67-15.49)
Androstenedione	µg/l	70 (59-88)	66 (53-78)	58 (48-67)
Free PSA %	%	16 (0.30-25)	11 (0.24-20)	8 (0.18-17.50)
DHEA-Sulfate	µg/ml	1.23 (0.76-1.75)	1.06 (0.69-1.47)	0.76 (0.54-1.14)
Sex Hormone Binding Globulin	nmol/l	43 (32-53)	46 (35-58)	48 (35.5-62)
Prostate volume	ml	61.32 (45-81.97)	46.37 (34-66.45)	45 (33.94-60)
PSAD	ng/ml/ml	0.1 (0.07-0.13)	0.13 (0.08-0.19)	0.21(0.16-0.35)
Positive family history	Count, %	12 (9.83)	14 (11.97)	7 (16.28)
Positive DRE	Count, %	10 (8.20)	72 (61.54)	21 (48.84)
PIRADS ≤2	Count, %	19 (15.57)	6 (5.13)	0 (0)
PIRADS 3	Count, %	44 (36.07)	23 (19.66)	1 (2.33)
PIRADS 4	Count, %	53 (43.44)	58 (49.57)	14 (32.56)
PIRADS 5	Count, %	6 (4.92)	30 (25.64)	28 (65.12)

583

584

585 **Figure 1: Statistically significant associations with the presence of moderate or**
586 **aggressive PC**

587 **A** Statistically significant association between laboratory parameters and the
588 presence of ISUP 1-2 PC, ISUP 3-5 PC, or healthy patients. **B** Statistically significant
589 associations between clinical and imaging parameters and the presence of ISUP 1-2
590 PC, ISUP 3-5 PC or healthy patients.

591

592 **Figure 2: Risk modeling of PC**

593 **A** Performance metric of a logistic classifier based on five sets of features: 1. PSA, 2.
594 Integration of additional laboratory biomarkers, 3. Integration of clinical factors, 4.
595 Integration of MRI results and 5. Solely PSA and MRI as comparison. **B** Feature
596 importance for the three groups (healthy patients, ISUP 1-2 PC and ISUP 3-5 PC).



597



598 **Figure 3: SHAP analysis to obtain per-patient SHAP values**


599 SHAP values for two patients of the cohort who had no PC in the prostate biopsy:
600 blue color indicates a reduction of the probability of having PC, and orange color
601 indicates an increased probability of having PC.

602

603

A**B**

A**B**

A**B**